| Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial K Cusi, B Orsak, F Bril, R Lomonaco, J Hecht, C Ortiz-Lopez, F Tio, ... Annals of internal medicine 165 (5), 305-315, 2016 | 984 | 2016 |
| High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels P Portillo-Sanchez, F Bril, M Maximos, R Lomonaco, D Biernacki, B Orsak, ... The journal of clinical endocrinology & metabolism 100 (6), 2231-2238, 2015 | 608 | 2015 |
| Modulation of insulin resistance in nonalcoholic fatty liver disease RS Khan, F Bril, K Cusi, PN Newsome Hepatology 70 (2), 711-724, 2019 | 398 | 2019 |
| Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action F Bril, K Cusi Diabetes care 40 (3), 419-430, 2017 | 374 | 2017 |
| Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease K Cusi, Z Chang, S Harrison, R Lomonaco, F Bril, B Orsak, C Ortiz-Lopez, ... Journal of hepatology 60 (1), 167-174, 2014 | 314 | 2014 |
| Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies NE Sunny, F Bril, K Cusi Trends in Endocrinology & Metabolism 28 (4), 250-260, 2017 | 270 | 2017 |
| Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial F Bril, DM Biernacki, S Kalavalapalli, R Lomonaco, SK Subbarayan, J Lai, ... Diabetes care 42 (8), 1481-1488, 2019 | 255 | 2019 |
| Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease F Bril, D Barb, P Portillo‐Sanchez, D Biernacki, R Lomonaco, A Suman, ... Hepatology 65 (4), 1132-1144, 2017 | 242 | 2017 |
| Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients F Bril, C Ortiz‐Lopez, R Lomonaco, B Orsak, M Freckleton, K Chintapalli, ... Liver International 35 (9), 2139-2146, 2015 | 223 | 2015 |
| Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening R Lomonaco, E Godinez Leiva, F Bril, S Shrestha, L Mansour, J Budd, ... Diabetes Care 44 (2), 399-406, 2021 | 218 | 2021 |
| Nonalcoholic fatty liver disease: current issues and novel treatment approaches R Lomonaco, NE Sunny, F Bril, K Cusi Drugs 73, 1-14, 2013 | 217 | 2013 |
| Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? F Bril, S Al Diffalha, M Dean, DM Fettig Journal of Hepatology 75 (1), 222-224, 2021 | 214 | 2021 |
| The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease M Maximos, F Bril, P Portillo Sanchez, R Lomonaco, B Orsak, D Biernacki, ... Hepatology 61 (1), 153-160, 2015 | 212 | 2015 |
| Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD F Bril, JJ Sninsky, AM Baca, HR Superko, P Portillo Sanchez, D Biernacki, ... The Journal of Clinical Endocrinology & Metabolism 101 (2), 644-652, 2016 | 182 | 2016 |
| Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes F Bril, S Kalavalapalli, VC Clark, R Lomonaco, C Soldevila-Pico, IC Liu, ... Clinical Gastroenterology and Hepatology 16 (4), 558-566. e2, 2018 | 179 | 2018 |
| Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis F Bril, R Lomonaco, B Orsak, C Ortiz‐Lopez, A Webb, F Tio, J Hecht, ... Hepatology 59 (6), 2178-2187, 2014 | 172 | 2014 |
| Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes R Lomonaco, F Bril, P Portillo-Sanchez, C Ortiz-Lopez, B Orsak, ... Diabetes care 39 (4), 632-638, 2016 | 156 | 2016 |
| Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes K Cusi, F Bril, D Barb, D Polidori, S Sha, A Ghosh, K Farrell, NE Sunny, ... Diabetes, Obesity and Metabolism 21 (4), 812-821, 2019 | 155 | 2019 |
| Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus F Bril, K Cusi Endocrinology and Metabolism Clinics 45 (4), 765-781, 2016 | 146 | 2016 |
| Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes F Bril, MJ McPhaul, MP Caulfield, VC Clark, C Soldevilla-Pico, ... Diabetes care 43 (2), 290-297, 2020 | 141 | 2020 |
